Scienture vs XTL Biopharmaceuticals
SCNX and XTLB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SCNX and XTLB compare
Scienture scores higher on the StockData Score (3 against 0 for XTL Biopharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SCNX | XTLB |
|---|---|---|
| Size and price | ||
| Market cap | $123M | – |
| Share price | $2.99 | $1.54 |
| Change, 1 year | −82.2% | −59.1% |
| Change, 5 years | −99.8% | −87.1% |
| Beta (5Y) | 1.07 | 1.21 |
| Employees | 8 | 3 |
| StockData Score | ||
| Total score | 3 (better) | 0 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 1.9× | – |
| Growth | ||
| Revenue growth, 5Y average | −52.1% | – |
| Profitability | ||
| Return on equity | −53.5% | – |
| Return on invested capital | −47.3% | – |
| Financial health | ||
| Interest coverage | −13.1× | −6.3× (better) |
| Current ratio | 3.04 | – |
| Altman Z-score | 0.31 | – |
| Piotroski F-score | 4 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | – | 0.00% |
| Held by insiders | 16.6% | 0.00% |
| Short interest, % of float | 0.34% | – |
Go deeper
- SCNX stock overview
- SCNX income statement
- SCNX valuation and score
- XTLB stock overview
- XTLB income statement
- XTLB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.